SOPHIA ANTIPOLIS, France, Jan. 6, 2014 (GLOBE NEWSWIRE) -- Nicox S.A. (NYSE Euronext Paris: COX) today provides a summary of its progress in 2013. In line with the strategy announced in 2012, Nicox is making rapid progress in building an international ophthalmic company with a range of ophthalmic diagnostics and eye care products marketed in the United States and in Europe. During this important evolution year, the Company launched Sjö, a novel diagnostic test, in the United States, acquired Eupharmed in Italy and saw its lead R&D asset latanoprostene bunod enter Phase 3 for glaucoma. The Company intends to continue expanding its portfolio through in-licensing, distribution and acquisition agreements.
Help employers find you! Check out all the jobs and post your resume.
